TELO

Telomir Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website elomirpharma.com
Employees(FY) 2
ISIN US87975F1049

Performance

+1.77%

+16.67%

-22.69%

-7.17%

+3.6%

YTD

+3.6%

Profile

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Advanced Technical Analysis

Technical Analysis of TELO 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 83, indicating robust upward momentum, while the Technical Score of 63 supports this positive outlook. However, the Oscillators Score of 43 suggests a neutral stance, indicating potential caution in the short term despite the overall bullish trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TELO

Stock Rank

Recent News & Updates

2024-12-11 19:30
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price(Accesswire)
2024-12-02 18:30
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1(Yahoo Finance)
2024-11-20 18:00
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1(Accesswire)
2024-09-26 04:00
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday(Accesswire)
2024-09-03 19:30
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications(Accesswire)
2024-08-19 19:30
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs(Accesswire)
2024-08-11 20:30
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman(Globenewswire)
2024-07-01 20:30
Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes(Globenewswire)
2024-06-17 04:10
Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel(Globenewswire)
2024-05-29 20:30
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1(Globenewswire)
2024-05-23 21:30
New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET(Globenewswire)
2024-05-15 21:30
Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support(Globenewswire)
2024-05-13 10:53
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024(Investorplace)
2024-05-07 03:02
Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1(Newsdirect)
2024-04-15 20:30
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.(Globenewswire)
2024-04-01 20:30
Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024(Globenewswire)
2024-03-29 04:44
UPDATE Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines(Globenewswire)
2024-03-25 20:30
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines(Globenewswire)
2024-03-21 20:30
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th(Globenewswire)
2024-03-13 20:30
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science(Globenewswire)
2024-03-06 19:30
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference(Globenewswire)
2024-03-04 19:30
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal(Globenewswire)
2024-02-13 03:05
Telomir Pharmaceuticals Announces Closing of Initial Public Offering(Globenewswire)

Page 1 of 1

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.